Albumin Nanoparticle–Mediated Codelivery of Regorafenib and Paclitaxel Boosts Chemoimmunotherapy of Peritoneal Metastases
Small Methods · 2026
DOI: 10.1002/smtd.71021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, 2026. Verfasst von Meng-Ting Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, South China University of Technology, Guangzhou, China. Hauptthemen laut MEDLINE: Paclitaxel, Albumins, Peritoneal Neoplasms, Nanoparticles. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Science and Technology Planning Project, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Despite its well‐established clinical efficacy in multiple solid tumors, nab‐paclitaxel confers limited therapeutic benefit in metastatic colorectal cancer (mCRC), primarily attributed to intrinsic chemoresistance and macrophage‐mediated immunosuppression. Here, we find that regorafenib (REG) and paclitaxel (PTX) exhibit robust synergistic cytotoxicity against tumor cells, while also potentiating repolarization of macrophages from pro‑tumor M2 to antitumor M1 phenotype. To leverage this synergy and improve the therapeutic efficacy of albumin‐bound PTX in mCRC, we construct an albumin nanoparticle co‐loaded with REG and PTX (Alb‐RP). Alb‐RP facilitates macrophage phenotypic transition to the M1 state and upregulates proinflammatory cytokine expression, exhibiting potent tumoricidal activity in macrophage‐tumor cell co‐culture systems. In the MC38 colorectal peritoneal metastasis (CPM) model, Alb‐RP markedly suppresses tumor progression and prolongs survival, achieving complete tumor regression in 44% of treated mice. Meanwhile, Alb‐RP effectively reshapes the immune microenvironment in both peritoneal fluid and tumor tissues, characterized by decreased M2 macrophages, expanded M1 macrophages, enhanced dendritic cell activation, and increased infiltration of cytotoxic CD8 + T cells. Collectively, this study presents a translatable albumin‐based co‐delivery strategy that integrates direct chemotherapeutic cytotoxicity and macrophage repolarization to overcome the limited efficacy of albumin‐bound PTX against mCRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, South China University of Technology, Guangzhou, China.
- Medical Devices Research & Testing Center, South China University of Technology, Guangzhou, China.
- Science and Technology Innovation Center of Guangzhou University of Chinese Medicine, Guangzhou, China.
- National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, China.
- Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, and Guangdong Provincial Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou, China.
ORCID-Profile: Meng-Ting Lin, Jin-Zhi Du
Förderung
- National Natural Science Foundation of China
- Guangzhou Science and Technology Planning Project
- China Postdoctoral Science Foundation
Zitieren
APA
Lin, M. T., Pan, Y. N., Liu, J. Y., Zhuang, Z. H., Han, S. Y., Jia, H. H., Zhang, J. Y., & Du, J. Z. (2026). Albumin Nanoparticle–Mediated Codelivery of Regorafenib and Paclitaxel Boosts Chemoimmunotherapy of Peritoneal Metastases. Small Methods. https://doi.org/10.1002/smtd.71021
Vancouver
Lin MT, Pan YN, Liu JY, Zhuang ZH, Han SY, Jia HH, et al. Albumin Nanoparticle–Mediated Codelivery of Regorafenib and Paclitaxel Boosts Chemoimmunotherapy of Peritoneal Metastases. Small Methods. 2026. doi:10.1002/smtd.71021
BibTeX
@article{Lin2026,
author = {Lin, Meng-Ting and Pan, Yuan-Na and Liu, Jing-Yi and Zhuang, Zhen-Hao and Han, Si-Yao and Jia, Huan-Huan and Zhang, Jing-Yang and Du, Jin-Zhi},
title = {Albumin Nanoparticle–Mediated Codelivery of Regorafenib and Paclitaxel Boosts Chemoimmunotherapy of Peritoneal Metastases},
journal = {Small Methods},
year = {2026},
doi = {10.1002/smtd.71021}
}
EUVIMED